ideal T responders), and all T levels recorded were obtained subsequent to achieving a T level 0.7 ng/mL. Serum T levels were measured using a chemiluminescent microparticle immunoassay (Abbott Diagnosticsâ ARCHITECT i2000). Statistical significance was set at p¼0.05. Analysis was performed using SPSS v23.0.
INTRODUCTION AND OBJECTIVES: Although visceral metastases (VM) are widely recognized to portend worse prognoses compared to bone and lymph metastases in prostate cancer, currently little is known about what predicts VM and the extent to which men with VM do worse, particularly at the time of initial diagnosis of metastatic castration-resistant prostate cancer (mCRPC). Our study aimed to determine whether men with VM at initial mCRPC diagnosis have worse overall survival and identify predictors of VM.
METHODS: We analyzed 494 men diagnosed with CRPC post-1999 and no known metastases from five Veterans Affairs hospitals of the SEARCH database who later developed metastases. Radiology scans (bone scan, MRI, CT scan, X-ray) within 30 days of initial metastasis diagnosis were reviewed to collect information on bone, visceral, and lymph node metastases. We analyzed the 236 men who had a CT scan performed. Predictors of VM and overall survival were evaluated using logistic regression and Cox models, respectively. Variables included age, year, race, treatment center, biopsy Gleason, primary localized treatment, metastases in lymph nodes, PSA, PSA doubling time, time from androgen deprivation therapy to CRPC, and time from CRPC to metastases.
RESULTS: Of the 236 mCRPC patients, 38 (16%) had VM. Regarding VM, 19 (50%), 8 (21%), and 16 (42%) patients had metastases in the liver, lungs, and other locations, respectively. VM was a predictor of overall survival on crude analysis (HR¼1.88, 95% CI 1.30-2.72, p¼0.001) and after risk adjustment (HR¼1.84; 95% CI 1.24-2.72, p¼0.002). Age, year, treatment center, PSA, and time from CRPC to metastases were significant in predicting overall survival (all p<0.05). None of the variables tested were associated with having VM (all p>0.09).
CONCLUSIONS: Neither demographic, tumor, nor PSA-kinetic characteristics were predictive of having VM, but VM predicted worse overall survival. There are currently no known clinical predictors of VM; however, since patients with VM have worse overall survival, there remains a need for further research to determine what predicts VM. Efforts targeted at identifying novel biomarkers for VM have the potential to have the greatest impact for those suffering from this particular disease state.
Source of Funding: None

PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER
Bertram Yuh, Duarte, CA; Young Suk Kwon*, Brian Shinder, Sinae Kim, Nara Lee, New Brunswick, NJ; Nora Ruel, Duarte, CA; Shigeo Horie, Tokyo, Japan; Seok-Soo Byun, Seongnam-Si, Korea, Republic of; Dong Hyeon Lee, Seoul, Korea, Republic of; Robert Dipaola, Isaac Yi Kim, New Brunswick, NJ INTRODUCTION AND OBJECTIVES: Emerging evidence has suggested that local tumor control may enhance the effect of subsequent therapies in patients with metastatic prostate cancer. However, little is known about surgical safety of cytoreductive prostatectomy (CRP). In this study, we report the first interim analysis of a phase I study evaluating the safety and feasibility of CRP.
METHODS: The study was approved by the IRB and activated in June, 2015. Individuals with newly diagnosed clinical metastatic prostate cancer to lymph node and bones (cT1-3N1M0 or cT1-3N0M1a-b) were recruited. Men with visceral metastasis (M1c) or ECOG PS 2 were not eligible. Following surgery, all patients received androgen deprivation therapy. The primary endpoint is the major complication rate. The secondary outcome measures are the time to PSA nadir and rate of incontinence (pad-free).
RESULTS: A total of 21 patients from two institutions have been enrolled and undergone CRP. Of the 20 patients with complete data, the median (range) age at surgery was 62 (53-73). Overall, six (35.3%) perioperative complications were observed, including one major complication (Clavien III or higher). There were five minor complications, including deep venous thrombus (Clavien II), postoperative ileus (Clavien II), and three cases of urethral anastomotic leaks (Clavien I). In men with minimum of 6 month follow-up, 63.6% of men had PSA < 0.2 ng/ml, and 50% of men were pad free (Table 1) .
CONCLUSIONS: CRP is surgically feasible in carefully selected patients. However, early incontinence rate is high. Further studies are warranted to further define long-term complications and verify the oncologic benefits of the surgery.
INTRODUCTION AND OBJECTIVES:
The paradigm of first testing systemic treatments in advanced disease followed by development in earlier disease states and finally large-scale trials evaluating whether the approach, in combination with local therapy, can prevent or delay the time-to-event measures of disease progression or death in patients with 00 high-risk 00 tumors is no longer practical now that 6 lifeprolonging systemic therapies in metastatic castration-resistant prostate cancer are available. Our objective was to evaluate a multimodal treatment platform and a short term endpoint of treatment efficacy as a new strategy to rapidly evaluate and prioritize regimens for large-scale phase 3 testing.
METHODS: We conducted a pilot study of twenty men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis. All sites of disease were treated using a multimodal approach that included androgen deprivation (ADT), radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease and/or the primary site. ADT was discontinued in responding patients. Outcomes of each treatment were assessed sequentially. The primary endpoint of 00 no evidence of disease 00 (NED) was defined by an undetectable PSA (<0.05 ng/mL) with noncastrate levels of testosterone at 20 months (>150 ng/dL).
RESULTS: Each treatment modality contributed to the outcome: 95% of the cohort achieved an undetectable PSA with multimodal treatment, including 25% of patients after ADT alone and an additional 50% and 20% after surgery and radiotherapy, respectively. Overall, 20% of patients (95% confidence interval 3-38%) achieved the primary endpoint, which persisted for 5, 6, 27+, and 46+ months. All patients meeting the primary endpoint had been classified with M1b disease at presentation. CONCLUSIONS: Treatment directed at all sites can eliminate detectable disease in selected patients with newly diagnosed metastatic prostate cancer. A multimodal treatment strategy inclusive of the NED endpoint for patients who present with disease that is beyond the limits of curability by any single modality should be considered to enable the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease. The PROCEED registry provides a prospective opportunity to confirm these observations in a larger group of AA pts.
Source of
METHODS: PROCEED (NCT01306890) enrolled men with mCRPC. In this analysis, two Caucasian (CAU) pts were matched to each AA pt by baseline prostate-specific antigen (PSA), as PSA correlates with OS in pts receiving sip-T (Schellhammer 2013). OS and time to first anticancer intervention (tACI) post-sip-T were examined; univariate and multivariate analyses evaluated independent factors associated with OS.
RESULTS: 420 CAU pts were matched to 210 AA pts; all received 1 sip-T infusion. CAU pts had significantly higher baseline median hemoglobin levels (p<0.001; 13.0 g/dL vs 12.1 g/dL for AA pts) and were more likely to receive prior local therapy (p¼0.02) or prior chemotherapy (p<0.001). CAU pts had a longer tACI of 9.3 mo vs 7.6 mo for AA pts. However, AA pts had a significantly longer median OS of 39.5 mo vs 28.1 mo for CAU pts (p<0.001; HR 0.665, 95% CI 0.530-0.835). After univariate and multivariate analyses, six baseline characteristics were significantly associated with OS (Table) . Younger age, lower PSA or alkaline phosphatase, and higher hemoglobin levels were independently associated with longer OS. No prior chemotherapy and the AA race were also independent predictors of extended OS.
CONCLUSIONS: Post-sip-T, median OS for AA pts was significantly extended by nearly 1 year compared with matched CAU pts. In this large prospective analysis, AA race emerged as an independent predictor of longer OS in multivariate analyses, confirming observations of prior retrospective analysis of phase 3 trial data. These results should stimulate additional studies on the biologic basis for AA men's enhanced response to sip-T and potentially other immunotherapies.
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